See other companies on Welcome to the Jungle
Relay Therapeutics
AI-driven drug discovery platform
- 201-500 employees
- Healthcare
- B2B
- Artificial Intelligence
- Machine Learning
- MedTech
- Wellington-Harrington, Cambridge, MA
Jump to section
Company mission
Relay Therapeutics' mission is to create new possibilities in drug discovery focused on precision oncology and genetic disease through its AI and ML-driven computing approaches.
9% employee growth in 12 months
Our take
Discovering new drugs is essential in improving how diseases are treated, but existing methods are outdated. Many diseases are highly complex and have so far been impossible to treat with drugs, but developments in AI-driven computing present the potential to change this.
Relay Therapeutics provides an AI-driven drug discovery platform called Dynamo that uses cutting-edge experimental computational approaches to identify disease treatments that have previously been deemed untreatable. The platform's AI approach is driven by a pipeline of therapeutic candidates which hold an initial focus on precision oncology and genetic disease treatment.
AI is being used within the medical industry to aid in a wide variety of scenarios such as facility optimization and automated diagnoses, but Relay Therapeutics has smartly applied it to drug discovery. Through this more targeted approach, the company aims to rapidly develop genetic disease treatments and optimize the process of precision oncology, with plans to expand into further disciplines in the future. It's continued development of new products shows that Relay is keeping up the pace.
Steph
Company Specialist at Welcome to the Jungle
Benefits
- Medical coverage
- Dental coverage
- Vision coverage
- Life, AD&D, and disability insurance
- Flexible spending accounts
- 401K retirements savings
- Commute reimbursements
- Parental benefits
- Time off and vacation
Company values
- The little things really matter to us - we sweat every detail because we know it makes the difference time after time
- We're candid with each other - we have a responsibility to look into each other's eyes and agree, disagree, challenge, and succeed together
- We take great pride in our culture - come as you are because we embrace quirkiness. In fact, we thrive on it
- We value and respect different experiences - our inclusive culture encourages people to openly share their points of view
Funding (last 2 of 3 rounds)
Dec 2018
$400m
SERIES C
Dec 2017
$63m
SERIES B
Total funding: $520m
This company has top investors
Leadership
Mark Murcko
(Founder)Principal at Disruptive Biomedical, LLC since 2011. Senior Lecturer at the Department of Biological Engineering for MIT since 2012.